Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05794204 · ClinicalTrials.gov registry record · Phase 2
RMP-A03 Ocular Suspension in Patients With Pterygium
A Phase 2 study of Pterygium, sponsored by Suzhou Raymon Pharmaceuticals Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 6
- Study locations
NCT05794204 is a Phase 2 study of Pterygium that has completed, run by Suzhou Raymon Pharmaceuticals Company. The registered enrollment target is 77 participants, below the 240-participant average among 3 other Pterygium trials with a reported enrollment target (68% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT05794204, a Phase 2 study of Pterygium, has completed, sponsored by Suzhou Raymon Pharmaceuticals Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.
Conditions Studied
Interventions
- DRUG RMP-A03 - Dose 1
- DRUG RMP-A03 - Dose 2
- DRUG RMP-A03 Placebo
Study Locations (6)
California
- Global Research Management - Glendale
- United Medical Research Institute - Inglewood
- Eye Research Foundation Inc - Newport Beach
Florida
- Oceane7 Medical & Research Center Inc. - Miami
Tennessee
- Toyos Clinic - Nashville
Texas
- Keystone Research - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2023-06-09 |
| Est. Completion | 2024-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05794204
The ClinicalTrials.gov registry entry for NCT05794204 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 3 other Pterygium trials with a reported enrollment target (68% lower). The listed sponsor is Suzhou Raymon Pharmaceuticals Company, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pterygium appearing as the primary indexed condition, and to 3 interventions - of which RMP-A03 - Dose 1 is the first listed.
NCT05794204 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05794204 about?
NCT05794204 is a clinical study titled "RMP-A03 Ocular Suspension in Patients With Pterygium". The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.
What is the current status of trial NCT05794204?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2023-06-09. Estimated completion is 2024-01-12.
What conditions does trial NCT05794204 study?
This clinical trial studies the following conditions: Pterygium.
What interventions are being tested in trial NCT05794204?
The interventions under investigation include: RMP-A03 - Dose 1 (DRUG), RMP-A03 - Dose 2 (DRUG), RMP-A03 Placebo (DRUG).
Who is sponsoring clinical trial NCT05794204?
This trial is sponsored by Suzhou Raymon Pharmaceuticals Company, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05794204 being conducted?
This trial has 6 study locations across California, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pterygium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.